Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.

Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Newron and Myung In Pharm have signed a licence agreement for evenamide, for schizophrenia treatment in South Korea.

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to ...

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.

The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.